Literature DB >> 7736321

The effect of different hormone replacement therapy regimens on the mechanical properties of rat vertebrae.

D Chachra1, M Kasra, C M Vanin, N J MacLusky, R F Casper, M D Grynpas.   

Abstract

The purpose of this study was to examine the effects of estrogen replacement, in concert with three different progestin regimens, on the mechanical properties of rat lumbar vertebrae. Ninety-two Sprague-Dawley rats (11 months old) were divided into six groups for treatment. The first group was an intact control, the second group (OVX) was ovariectomized only, and the third group (estrogen-only) was ovariectomized and received continuous estrogen through a 17 beta-estradiol implant. The remaining groups were ovariectomized and received estrogen and progestin (norethindrone, NET) therapy; 3 micrograms of NET was injected daily (estrogen plus continuous NET), or 6 micrograms of NET was injected for 14 consecutive days of a 28-day cycle (estrogen plus cyclic NET), or for 3 consecutive days of a 6-day cycle (estrogen plus interrupted NET). The animals were sacrificed after 6 months, and the vertebrae were dissected out. The vertebral processes of the fourth lumbar vertebrae were removed, and the density of the vertebral bodies was determined. They were then subjected to compression testing. We found that all three estrogen/progestin regimens maintain bone density and all mechanical properties at a level indistinguishable from the control. However, the cyclic and continuous NET treatment results were, with the exception of density, also indistinguishable from those of the ovariectomized group. The estrogen plus interrupted NET group on the other hand, has a significantly greater compressive modulus and density than the ovariectomized group. In conclusion, with respect to the ovariectomized group, the estrogen plus interrupted NET treatment resulted in a superior density and compressive modulus.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7736321     DOI: 10.1007/bf00296344

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  37 in total

1.  Estrogen replacement therapy I: a 10-year prospective study in the relationship to osteoporosis.

Authors:  L E Nachtigall; R H Nachtigall; R D Nachtigall; E M Beckman
Journal:  Obstet Gynecol       Date:  1979-03       Impact factor: 7.661

2.  Surface activity on the periosteal and corticoendosteal envelopes following continuous progestogen supplementation in spayed beagles.

Authors:  K K Karambolova; G R Snow; C Anderson
Journal:  Calcif Tissue Int       Date:  1986-04       Impact factor: 4.333

3.  Re-evaluating the role of progestogen therapy after the menopause.

Authors:  B E Henderson; R K Ross; R A Lobo; M C Pike; T M Mack
Journal:  Fertil Steril       Date:  1988-05       Impact factor: 7.329

Review 4.  Progesterone as a bone-trophic hormone.

Authors:  J C Prior
Journal:  Endocr Rev       Date:  1990-05       Impact factor: 19.871

5.  Biomechanical and biochemical changes in lumbar vertebrae of rapidly growing rats.

Authors:  G J Salem; R F Zernicke; A C Vailas; D A Martinez
Journal:  Am J Physiol       Date:  1989-01

6.  Estrogen binding, receptor mRNA, and biologic response in osteoblast-like osteosarcoma cells.

Authors:  B S Komm; C M Terpening; D J Benz; K A Graeme; A Gallegos; M Korc; G L Greene; B W O'Malley; M R Haussler
Journal:  Science       Date:  1988-07-01       Impact factor: 47.728

7.  The effects of 17 beta-estradiol and progestagen on trabecular bone remodeling in oophorectomized dogs.

Authors:  G R Snow; C Anderson
Journal:  Calcif Tissue Int       Date:  1986-09       Impact factor: 4.333

8.  Osteoporosis after oophorectomy in the mature female rat and the effect of oestrogen and-or progestogen replacement therapy in its prevention.

Authors:  J M Aitken; E Armstrong; J B Anderson
Journal:  J Endocrinol       Date:  1972-10       Impact factor: 4.286

9.  Oestrogen replacement therapy for prevention of osteoporosis after oophorectomy.

Authors:  J M Aitken; D M Hart; R Lindsay
Journal:  Br Med J       Date:  1973-09-08

10.  Glucocorticoid receptors and inhibition of bone cell growth in primary culture.

Authors:  T L Chen; L Aronow; D Feldman
Journal:  Endocrinology       Date:  1977-03       Impact factor: 4.736

View more
  6 in total

1.  Chlorthalidone improves vertebral bone quality in genetic hypercalciuric stone-forming rats.

Authors:  David A Bushinsky; Thomas Willett; John R Asplin; Christopher Culbertson; Sara P Y Che; Marc Grynpas
Journal:  J Bone Miner Res       Date:  2011-08       Impact factor: 6.741

2.  Anti-tumor effects of a novel retinoic acid metabolism blocking agent VN/14-1 in the N-methyl-N-nitrosourea-induced rat mammary carcinoma model and its effects on the uterus.

Authors:  Paul E Goss; Shangle Qi; Haiqing Hu; Lalji K Gediya; Puranik Purushottamachar; Abhijit M Godbole; Vincent C O Njar
Journal:  Breast Cancer Res Treat       Date:  2011-08-14       Impact factor: 4.872

3.  Genetic hypercalciuric stone-forming rats have a primary decrease in BMD and strength.

Authors:  Marc Grynpas; Stephen Waldman; Douglas Holmyard; David A Bushinsky
Journal:  J Bone Miner Res       Date:  2009-08       Impact factor: 6.741

4.  The selective estrogen receptor modulator SCH 57068 prevents bone loss, reduces serum cholesterol and blocks estrogen-induced uterine hypertrophy in ovariectomized rats.

Authors:  Paul E Goss; Shangle Qi; Angela M Cheung; Haiqing Hu; Maria Mendes; Kenneth P H Pritzker
Journal:  J Steroid Biochem Mol Biol       Date:  2004-09       Impact factor: 4.292

5.  Effect of rosiglitazone on bone quality in a rat model of insulin resistance and osteoporosis.

Authors:  Laura D Sardone; Richard Renlund; Thomas L Willett; Ivan G Fantus; Marc D Grynpas
Journal:  Diabetes       Date:  2011-10-12       Impact factor: 9.461

6.  Effects of low-magnitude, high-frequency mechanical stimulation in the rat osteopenia model.

Authors:  S Sehmisch; R Galal; L Kolios; M Tezval; C Dullin; S Zimmer; K M Stuermer; E K Stuermer
Journal:  Osteoporos Int       Date:  2009-03-13       Impact factor: 4.507

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.